Post Tagged with: "health"

Upgraded patient care areas opening at Royal Inland Hospital by Province of British Columbia https://flic.kr/p/2qeGUtB CC BY-NC-ND 2.0

The Law Bytes Podcast, Episode 228: Kumanan Wilson on Why Canadian Health Data Requires Stronger Privacy Protection in the Trump Era

The craziness of the Trump administration relationship with Canada was on full display this past week as seemingly every day involved some form of policy change on tariffs – first on, then slightly delayed for some goods, then slightly delayed for more goods and by week’s end threats of new tariffs. Given the uncertainty, I recently co-wrote an op-ed in the Globe and Mail together with Dr. Kumanan Wilson that sought to put the spotlight on another issue that could come to the fore if the economic battle moves beyond tariffs to other issues. In this case – privacy, data localization and health data.

Dr. Wilson is a specialist in General Internal Medicine at The Ottawa Hospital,  Chief Executive Officer/Chief Scientific Officer, Bruyère Research Institute, a Professor and Faculty of Medicine Clinical Research Chair in Digital Health Innovation at the University of Ottawa and member of the University of Ottawa’s Centre for Health Law, Policy and Ethics. He joins the Law Bytes podcast to discuss why we should be paying attention to health privacy, AI and the location of our data.

Read more ›

March 10, 2025 — 1 comment — Podcasts
Open government by Descrier http://descrier.co.uk https://flic.kr/p/pVRYzB (CC BY 2.0)

Canada’s Access to Information Open Data Fail: Departments Months Behind Posting Summaries of Completed Requests

The Liberal government has emphasized the importance of open data and open government policies for years, yet the government has at times disappointed in ways both big (Canada’s access-to-information laws are desperately in need of updating and the current bill does not come close to solving its shortcomings) and small (restrictive licensing and failure to comply with access to information disclosures).

Read more ›

June 26, 2018 — Comments are Disabled — News
Migraine Meds by Tanya (CC BY-NC-ND 2.0) https://flic.kr/p/eaDjxg

The Trouble With the TPP, Day 33: Setting the Rules for a Future Pharmacare Program

Earlier Trouble with the TPP posts focused on the health care implications of the agreement, focusing on patent term extensions, biologics protection, and limits on medical devices and pharma data collection. There is another health-related aspect of the TPP worthy of examination, but it is easy to miss. Chapter 26 of the TPP addresses transparency and anti-corruption, which is not the place you would expect to find provisions with a direct impact on health care. Yet Annex 26-A contains a full section on “transparency and procedural fairness for pharmaceutical products and medical devices.”  What does this section do?  The key aspect is to establish mandatory requirements for a national pharmacare program:

Read more ›

February 18, 2016 — 3 comments — News
Stethescope by Dan Wiedbrauk (CC BY-ND 2.0) https://flic.kr/p/mTmYTX

The Trouble with the TPP, Day 9: Limits on Medical Devices and Pharma Data Collection

The link between health care and the TPP’s intellectual property chapter is easy to spot, but there are other chapters with implications for the issue. The Trouble with the TPP series today considers Chapter 8, which covers Technical Barriers to Trade (TBT). The chapter contains some surprising restrictions on the ability for national regulators to require the disclosure of certain information as part of the regulatory review process for pharmaceutical products and medical devices (prior posts include Day 1: US Blocks Balancing Provisions, Day 2: Locking in Digital Locks, Day 3: Copyright Term Extension, Day 4: Copyright Notice and Takedown Rules, Day 5: Rights Holders “Shall” vs. Users “May”, Day 6: Price of Entry, Day 7: Patent Term Extensions, Day 8: Locking in Biologics Protection).

The Canadian government summary of the TBT chapter does not disclose that there are data collection restrictions. In fact, the only reference to the issue states that the chapter “improves regulatory transparency in the areas of cosmetics, medical devices, and pharmaceutical products.” Yet the chapter does far more than address regulatory transparency. For example, Annex 8-C 7bis requires each party to makes its determination on whether to grant marketing authorization for a specific pharmaceutical product on the basis on factors such as clinical data, manufacturing quality, and labelling information. However, it also states that:

Read more ›

January 14, 2016 — 4 comments — News